58-71-9CC(=O)OCC1=C(C(=O)[O-])N2C(=O)[C@@H](NC(=O)Cc3cccs3)[C@H]2SC1.[Na+]VUFGUVLLDPOSBC-XRZFDKQNSA-MCephalothin sodium is an organic sodium salt. It contains a cefalotin.
58-71-9DTXSID30891362CHEMBL1632CHEBI:3542FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Danger
H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]
P233, P260, P261, P271, P272, P280, P284, P302+P352, P304+P340, P321, P333+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 58 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
REACH registered substance: Cefalotin sodium (EC: 200-394-6)
5-Thia-1-azabicyclo4.2.0oct-2-ene-2-carboxylic acid, 3-(acetyloxy)methyl-8-oxo-7-(2-thienylacetyl)amino-, monosodium salt, (6R,7R)-: Does not have an individual approval but may be used under an appropriate group standard
개요Cefalothin is a β-lactam cephalosporin antibiotic. It inhibits the growth of various Gram-positive and Gram-negative bacteria, including several strains of S. pyogenes, S. aureus, C. tetani, N. gonorrhoeae, Salmonella, and Shigella (MICs = 0.1-0.2, 0.312-0.625, 0.078, 1.25, 1.56-6.25, and 3.12-12.5 μg/ml, respectively). Cefalothin binds to E. coli penicillin-binding proteins (PBPs; IC50s = S. pyogenes, D. pneumoniae, and S. aureus. Formulations containing cefalothin were previously used in the prophylaxis and treatment of bacterial infections.
용도Cephalothin sodium salt is used to study the mechanism of liposome encapsulated antibiotics1, strategies for co-opting β-lactamases of Gram-negative bacteria for treatment of antibiotics2, and for immunology studies in relation to antibiotics.3 It is used to study the effect of expression, binding and inhibition of penicillin-binding proteins especially PBP6 on bacterial cell wall mucopeptide synthesis.
일반 설명Cephalothin, along with cephaloridine, was the first of the synthetic cephalosporin C class antibiotics to be introduced clinically. It was synthesized from 7-amino-cephalosporanic acid by Lilly Research Laboratories in 1962. Cephalothin shows strong activity against gram-positive and gram-negative bacteria and Leptospira, including benzylpenicillin-resistant strains. It has been used intravenously and intramuscularly to treat a variety of infections caused by Staphylococcus, Streptococcus, Escherichia coli, and Neisseria. The drug is metabolized in vivo, and the metabolite, deacetylcephalothin, is almost inactive.
Crystalline